|Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3, 4-methylenedioxymethamphetamine in rats: involvement of the V1 A receptor|
L Ramos, C Hicks, R Kevin, A Caminer, R Narlawar, M Kassiou, ...
Neuropsychopharmacology 38 (11), 2249-2259, 2013
|The nonpeptide oxytocin receptor agonist WAY 267,464: Receptor‐binding profile, prosocial effects and distribution of c‐Fos expression in adolescent rats|
C Hicks, W Jorgensen, C Brown, J Fardell, J Koehbach, CW Gruber, ...
Journal of neuroendocrinology 24 (7), 1012-1029, 2012
|Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non‐peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study …|
C Hicks, L Ramos, T Reekie, GH Misagh, R Narlawar, M Kassiou, ...
British journal of pharmacology 171 (11), 2868-2887, 2014
|Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion|
CP Motbey, E Karanges, KM Li, S Wilkinson, AR Winstock, J Ramsay, ...
PloS one 7 (9), 2012
|Adolescent pre‐treatment with oxytocin protects against adult methamphetamine‐seeking behavior in female rats|
C Hicks, JL Cornish, SJ Baracz, A Suraev, IS McGregor
Addiction biology 21 (2), 304-315, 2016
|Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood|
AS Suraev, MT Bowen, SO Ali, C Hicks, L Ramos, IS McGregor
Hormones and behavior 65 (5), 488-496, 2014
|Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator|
RA Gregg, C Hicks, SU Nayak, CS Tallarida, P Nucero, GR Smith, ...
Neuropharmacology 108, 111-119, 2016
|Oxytocin and MDMA (‘Ecstasy’) enhance social reward in rats|
L Ramos, C Hicks, A Caminer, J Goodwin, IS McGregor
Psychopharmacology 232 (14), 2631-2641, 2015
|Inhaled vasopressin increases sociability and reduces body temperature and heart rate in rats|
L Ramos, C Hicks, A Caminer, IS McGregor
Psychoneuroendocrinology 46, 46-51, 2014
|Synthetic cathinones and stereochemistry: S enantiomer of mephedrone reduces anxiety-and depressant-like effects in cocaine-or MDPV-abstinent rats|
HL Philogene-Khalid, C Hicks, AB Reitz, LY Liu-Chen, SM Rawls
Drug and alcohol dependence 178, 119-125, 2017
|Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059|
C Hicks, L Ramos, B Dampney, SJ Baracz, IS McGregor, GE Hunt
Brain research bulletin 127, 208-218, 2016
|WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action|
C Hicks, L Ramos, TA Reekie, R Narlawar, M Kassiou, IS McGregor
Psychopharmacology 232 (15), 2659-2667, 2015
|Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG)|
C Hicks, RA Gregg, SU Nayak, LA Cannella, GJ Schena, CS Tallarida, ...
Psychopharmacology 234 (11), 1671-1681, 2017
|Sigma receptors and substance use disorders|
V Sabino, C Hicks, P Cottone
Sigma Receptors: Their Role in Disease and as Therapeutic Targets, 177-199, 2017
|DARK classics in chemical neuroscience: cathinone-derived psychostimulants|
SJ Simmons, JM Leyrer-Jackson, CF Oliver, C Hicks, JW Muschamp, ...
ACS chemical neuroscience 9 (10), 2379-2394, 2018
|Dopamine D1-like receptor agonist and D2-like receptor antagonist (−)-stepholidine reduces reinstatement of drug-seeking behavior for 3, 4-methylenedioxypyrovalerone (MDPV) in rats|
C Hicks, P Huang, L Ramos, SU Nayak, Y Caro, AB Reitz, GR Smith, ...
ACS chemical neuroscience 9 (6), 1327-1337, 2018
|MDMA (‘Ecstasy’), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors|
L Ramos, C Hicks, A Caminer, K Couto, R Narlawar, M Kassiou, ...
Pharmacology Biochemistry and Behavior 150, 115-123, 2016
|Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences|
A Wong, K Keats, K Rooney, C Hicks, DJ Allsop, JC Arnold, IS McGregor
Psychopharmacology 231 (20), 3987-3996, 2014
|Therapeutic compounds and compositions for treating social disorders and substance use disorders|
IS McGregor, M Kassiou, MT Bowen, C Hicks, W Jorgensen
US Patent App. 15/738,532, 2019
|Comparison of the effects of psychostimulant drugs of abuse on brain endothelial barrier integrity and extracellular microvesicle production|
AM Andrews, S Merkel, E Lutton, C Hicks, S Rawls, S Ramirez
Drug and Alcohol Dependence 100 (171), e9, 2017